Treatment of dry eye conditions

Details Treatment of dry eye conditions Treatment of dry eye conditions

2006-11-28

2010-11-02

Fay, Zohreh A (Department: 1612)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C514S912000

Reexamination Certificate

active

07825102

ABSTRACT:
The present invention provides a method for treating dry eye condition in an individual comprising administrating to said individual an amount of A3adenosine receptor (A3AR) agonist, the amount being effective to ameliorate symptoms of dry eye in the individual. In accordance with one embodiment, the dry eye condition is manifested by one or more ophthalmologic clinical symptoms selected from foreign body sensation, burning, itching, irritation, redness, eye pain, blurred vision, degraded vision and excessive tearing. A preferred A3RAg in accordance with the invention is N6-(3-iodobenzyl)-adenosine-5′-N-methyluronamide (IB-MECA).

REFERENCES:
patent: 5573772 (1996-11-01), Downey et al.
patent: 5688774 (1997-11-01), Jacobson et al.
patent: 5773423 (1998-06-01), Jacobson et al.
patent: 5780481 (1998-07-01), Jacobson et al.
patent: 99/06053 (1999-02-01), None
patent: 01/19360 (2001-03-01), None
patent: 02/083152 (2002-10-01), None
patent: 2004/029025 (2004-04-01), None
patent: 2006/011130 (2006-02-01), None
Holly, F.J.,“Tear Film Physiology,”International Ophthalmology Clinics, vol. 27, No. 1, pp. 2-6, (1987).

Affiliated with

Also associated with

Rating

Treatment of dry eye conditions does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of dry eye conditions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of dry eye conditions will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4191317